164 related articles for article (PubMed ID: 33743356)
1. Design and synthesis of novel (S)-Naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro/in vivo breast cancer models.
Han Mİ; Atalay P; Tunç CÜ; Ünal G; Dayan S; Aydın Ö; Küçükgüzel ŞG
Bioorg Med Chem; 2021 May; 37():116097. PubMed ID: 33743356
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, molecular modeling, in vivo study, and anticancer activity of 1,2,4-triazole containing hydrazide-hydrazones derived from (S)-naproxen.
Han MI; Bekçi H; Uba AI; Yıldırım Y; Karasulu E; Cumaoğlu A; Karasulu HY; Yelekçi K; Yılmaz Ö; Küçükgüzel ŞG
Arch Pharm (Weinheim); 2019 Jun; 352(6):e1800365. PubMed ID: 31115928
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, molecular modeling, in vivo study and anticancer activity against prostate cancer of (+) (S)-naproxen derivatives.
Birgül K; Yıldırım Y; Karasulu HY; Karasulu E; Uba AI; Yelekçi K; Bekçi H; Cumaoğlu A; Kabasakal L; Yılmaz Ö; Küçükgüzel ŞG
Eur J Med Chem; 2020 Dec; 208():112841. PubMed ID: 32998089
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract]
